(SERA) Sera Prognostics, Inc. Company Overview

What does Sera Prognostics do?

Sera Prognostics, Inc. is a Salt Lake City women’s health diagnostics company. It uses proteomics, bioinformatics, a clinically annotated biobank, and predictive algorithms to identify pregnancy risk from maternal blood, with testing delivered through a CLIA-certified central laboratory. Its operating model and risks are detailed in the 2025 Form 10-K.

Where does PreTRM fit in prenatal care?

PreTRM estimates the risk of spontaneous delivery before 37 weeks in singleton pregnancies. The assay uses the ratio of insulin-like growth factor binding protein 4 to sex hormone-binding globulin, supplemented by maternal height and weight. A validated 15% threshold identifies patients at more than twice average population risk, enabling targeted surveillance and preventive care.

Why does the problem matter economically?

Sera cites roughly 3.7 million U.S. births annually, with about one in ten babies born prematurely. Many cases occur without recognized risk factors. The company estimates an annual U.S. burden near $25 billion and an average expense of about $65,000 per preterm delivery, creating a health-economic case if guided care reduces severe outcomes and NICU use.

How does Sera Prognostics make money?

Sera operates a laboratory-service model. A clinician orders PreTRM, a maternal blood sample is collected, Sera performs the assay, and a risk report returns to the clinician. Revenue may come from insurers, government programs, health systems, employers, or patients. The main bottleneck is converting clinical evidence into routine ordering, contracted reimbursement, and reliable collections.

Why does reimbursement matter more than list price?

CMS assigned the PreTRM proprietary laboratory analysis code a $750 payment amount in 2021. That benchmark is not the same as realized revenue: collections depend on coverage, medical-necessity rules, contracted rates, claims acceptance, and patient responsibility. A diagnostic can show clinical utility yet remain commercially weak if orders face denials or unpredictable bills.

PreTRM is the economic engine and commercial proof point. LikeMine, a beta pregnancy-data application, and a broader risk panel are possible extensions, alongside research in preeclampsia, fetal growth restriction, gestational diabetes, stillbirth, and postpartum depression. These programs are options, not current segments; valuation first depends on PreTRM reimbursement and adoption.

Why is clinical evidence the center of Sera’s strategy?

Sera’s commercial argument depends on intervention evidence. A risk score creates value only when clinicians can act on it and improve outcomes. PAPR enrolled 5,501 women at 11 U.S. centers, and TREETOP enrolled 5,011 women at 18 sites. Those cohorts validated biomarkers; PREVENT-PTB, AVERT, and PRIME tested whether risk-guided care changed outcomes.

What did PRIME show?

PRIME reported 20% reductions in NICU admissions and composite neonatal morbidity or mortality, plus 56% fewer births before 32 weeks and 32% fewer before 35 weeks. Sera calculated 4.2 patients screened and treated per NICU day saved and 38.5 per NICU admission averted. A July 2026 analysis of 1,783 first-time pregnancies found 22% fewer NICU admissions and a 30% relative reduction in severe morbidity, from 9.1% to 6.4%. See the July 2026 subgroup update.

AVERT reported an 18% reduction in severe neonatal morbidity or mortality. Among the longest stays, hospitalization was seven days shorter; babies born before 32 weeks stayed 28 fewer days. Pooled PRIME and AVERT data showed 22% reductions in prolonged hospital stay and composite morbidity or mortality, strengthening the payer case for avoided utilization.

Which turning points shaped Sera’s current position?

1. 2008
   Sera was incorporated, beginning a long development cycle around proteomic pregnancy biomarkers rather than a rapid software-style launch.
2. 2011–2014
   The PAPR program assembled a large U.S. pregnancy cohort, creating the biological and statistical foundation for PreTRM.
3. 2016–2019
   TREETOP independently validated the approach and expanded the company’s clinically annotated specimen and outcome database.
4. 2021
   Sera entered a commercial collaboration with Elevance Health and completed its initial public offering, funding the transition from research platform to commercial diagnostics company.
5. 2023
   PRIME enrollment was stopped early for efficacy, shifting the debate from whether the test predicts risk toward whether guided intervention can improve outcomes. Zhenya Lindgardt also became chief executive officer.
6. 2024–2025
   AVERT results and continued PRIME analysis broadened the utility evidence, while a February 2025 equity financing strengthened the balance sheet for commercialization.
7. 2026
   PRIME was published; Illinois advanced a Medicaid coverage initiative; Sera joined an ARPA-H-supported point-of-care project; and diagnostics executive Mark Capone joined the board effective July 1.

Sera is not yet a mature laboratory company. Most enterprise development funded datasets, biomarkers, and clinical utility; the current task is converting that evidence into coverage, ordering, and collections. This transition explains the greater emphasis on commercial hiring, payer engagement, and diagnostics operating expertise.

What changed after PRIME?

Before PRIME, Sera’s case rested mainly on predictive performance. Now management can discuss avoided NICU admissions and severe outcomes, which are more relevant to payers and health systems. Illinois is important because Medicaid finances about 43% of U.S. births and the state reports roughly 50,000 Medicaid births annually. The Illinois initiative could become a public-payer adoption model.

Why does the ARPA-H project matter?

A UC San Diego-led team received up to $10.4 million to develop a point-of-care maternal blood test for fetal hypoxia, with Sera contributing biomarker discovery and validation. The ARPA-H collaboration validates the platform beyond preterm birth, although it is not immediate commercial revenue.

What does Sera Prognostics’ latest quarter show?

Q1 2026 still reflects evidence translation and commercial investment rather than a scaled franchise. Revenue fell from $38,000 to $14,000 year over year, operating expenses were $9.4 million, net loss was $8.4 million, and operating cash use was $8.8 million. The Q1 2026 Form 10-Q provides the latest filing detail.

Why is revenue not yet the right scale metric?

Revenue is too small to reveal sustainable pricing, gross margin, or unit economics. Q1 2026 cost of revenue was $42,000, three times recognized revenue, so a gross-margin percentage would mislead. Better near-term indicators are covered lives, ordering sites, paid-test volume, claims acceptance, and realized payment per test—metrics Sera does not yet disclose as a recurring dashboard.

Where did spending shift?

R&D fell $0.3 million year over year while selling and marketing rose $0.5 million. Q1 2026 R&D included $1.629 million for research and bioinformatics, $0.740 million for clinical studies, and $0.661 million for laboratory operations, showing continued science investment alongside commercial expansion.

How financially strong is Sera Prognostics?

Sera’s balance sheet is stronger than its income statement. The February 2025 financing lifted cash and securities to $95.8 million at year-end 2025, before Q1 burn reduced the balance to $86.8 million. Management expects resources to fund significant milestones through 2029. Runway is time to prove adoption, not proof of self-funding.

What does the cash trend reveal?

How does capital allocation reflect the strategy?

FY2025 produced $0.081 million of revenue, $36.6 million of operating expenses, and a $31.9 million net loss. Capital is directed to evidence, payer work, laboratory capacity, commercial hiring, and pipeline research. Limited leverage reduces solvency risk, but additional equity may dilute holders if commercialization slips.

What gives Sera a competitive advantage?

Sera’s potential moat is a linked system: a clinically annotated pregnancy biobank, mass-spectrometry workflow, outcome data, predictive algorithms, and relationships with more than 60 investigators. A rival must reproduce both the assay and the longitudinal evidence that supports clinical action and payer value.

Why are the biobank and validation harder to copy?

Pregnancy datasets require correctly timed specimens, standardized processing, demographic context, and clinical follow-up. Sera’s independent validation cohorts make its evidence more defensible than a small convenience sample. At December 31, 2025, the portfolio included four issued U.S. patents, eight pending U.S. non-provisional applications, 30 granted foreign patents, and 34 pending foreign applications, with expirations expected from 2034 to 2046.

Where is the moat still unproven?

The moat is scientifically stronger than commercially proven. Competition can come from clinical risk scores, cervical-length screening, fetal fibronectin, large laboratories, molecular-diagnostics companies, and new biomarker platforms. Larger organizations may have superior distribution and payer contracts. If alternatives deliver acceptable outcomes with less workflow friction, Sera’s evidence advantage may not create pricing power.

Who owns Sera stock, and why does it matter?

Sera has one-vote Class A shares and non-voting Class B shares convertible one-for-one subject to ownership limits. It is not founder-controlled, but healthcare and specialist investors hold concentrated positions. The 2026 proxy statement uses approximately 39.2 million outstanding Class A and Class B shares as of April 13, 2026.

How concentrated is the disclosed ownership?

What do governance changes signal?

CEO Zhenya Lindgardt held 1.8% beneficial ownership in the proxy, and Executive Chair Gregory Critchfield held 4.2%. Mark Capone, formerly Myriad Genetics’ CEO, joined the board effective July 1, 2026. The appointment adds diagnostics commercialization experience when payer conversion and operating discipline are central.

What opportunities and risks could change the story?

What could accelerate adoption?

The largest opportunity is reimbursement momentum. A state Medicaid program, commercial payer, or integrated system can create a concentrated rollout and normalize ordering. Finger-prick collection, international expansion, and lower-cost assay formats could reduce friction, while additional pregnancy panels could raise revenue per patient and improve laboratory utilization.

Which risks are most material?

The leading risk is commercialization timing: payer review, guideline work, clinician education, and contracting can take years. Q1 2026 operating cash use of $8.8 million also makes delays dilutive. Centralized laboratory logistics, quality, cybersecurity, coding changes, and product concentration add operational risk. A negative coverage decision or challenge to PreTRM’s utility would affect nearly the entire business.

What is the key takeaway for valuation and research?

Sera is an evidence-rich but commercially unproven diagnostics platform. Historical revenue is too small for a trend DCF. A probability-weighted model should estimate eligible pregnancies, coverage, adoption, realized price, test cost, commercial expense, and time to scale.

Which variables deserve the most weight?

The key variables are payer conversion, clinician adoption, cash efficiency, and product breadth. Outcomes must become paid claims; ordering must become routine; milestones must arrive before new financing; and pipeline products must eventually improve use of the biobank and laboratory.

What should students, researchers, and investors monitor next?

The next evidence should be commercial: payer policies, recurring orders, paid-test volume, realized revenue, and laboratory cost. Also watch Illinois implementation, pipeline validation, quarterly cash burn, and new equity issuance. Board experience should be judged against milestone transparency.